Misdistribution of iron and oxidative stress in chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Biochemistry

Background:

• Chronic kidney disease (CKD) patients exhibit a significantly higher risk of cardiovascular diseases (CVD) compared to the general population.
• Systemic inflammation and oxidative stress are critical contributors to CVD morbidity and mortality in CKD.
• Dysregulation of iron metabolism is increasingly recognized as a potential driver of these complications.

Purpose of the Study:

• To review the mechanisms linking iron metabolism dysregulation to oxidative stress in CKD patients.
• To identify key factors contributing to increased oxidative stress in CKD.
• To explore the potential therapeutic role of erythropoiesis-stimulating agents (ESAs) in managing oxidative stress.

Main Methods:

• Literature review focusing on iron metabolism, oxidative stress, and CKD.
• Analysis of proposed mechanisms for oxidative stress in CKD.
• Evaluation of the potential impact of ESAs on these mechanisms.

Main Results:

• Four primary reasons for oxidative stress in CKD are proposed: 1) inflammatory cytokine and hepcidin-mediated iron sequestration, 2) reduced frataxin increasing mitochondrial free iron, 3) accumulation of toxic 5-aminolevulinic acid, and 4) leptin-induced hepcidin production.
• Excessive intracellular and mitochondrial iron accelerates the formation of toxic hydroxyl radicals, damaging cellular components.
• Current therapies for preventing oxidative stress in CKD are not well-defined.

Conclusions:

• Iron metabolism dysregulation significantly contributes to oxidative stress in chronic kidney disease patients.
• Erythropoiesis-stimulating agents (ESAs) used for renal anemia may potentially alleviate key causes of oxidative stress.
• Further clinical trials are essential to validate the effectiveness of ESAs in reducing oxidative stress in CKD.